Institute for Cancer Vaccines and Immunotherapy
Script error: No such module "Draft topics".
Script error: No such module "AfC topic".
| Formation | 2000 |
|---|---|
| Type | Charitable organisation |
| Registration no. | England and Wales: 1080343 |
| Purpose | Cancer research |
| Headquarters | Unit 15, Abbeville Mews 88 Clapham Park Road London SW4 7BX |
| Website | https://icvi.org.uk/ |
Formerly called | Cancer Vaccine Institute |
The Institute for Cancer Vaccines and Immunotherapy (ICVI) is a UK based charity focused on research into Immunotherapy as a treatment for Cancer. Its principal is Professor Angus Dalgleish.
History[edit]
In 1994, St George's Hospital launched the Cancer Vaccine Campaign to finance the building of facilities for cancer vaccine research and to allow Professor Dalgleish to continue his work on a vaccine for Melanoma.[1] In 2000 additional funds were required to continue the work so a fundraising initiative to raise £2 million was started in order to establish the Cancer Vaccine Institute (now the Institute for Cancer Vaccines and Immunotherapy) at St George’s.[2]
Research[edit]
At present, most of the research takes place at St George’s University of London. There have been collaborative and side projects run with Public Health England, UCL and Cardiff University. The subject of research is often determined by Professor Dalgleish’s work with his patients and mainly revolves around cancer immunotherapy, whereby the immune system is stimulated to engage its natural fight against the cancerous cells. Other research currently funded by ICVI includes but is not limited to:
- Understanding T cell approaches as cancer immunotherapies.[3]
- Cellular approaches to cancer treatment.[4]
- The effect of drugs on the immune response to vaccination.[5]
See also[edit]
References[edit]
- ↑ "Just £2 could save hundreds of lives". Guardian. June 12, 1995.
- ↑ Peake, Alex (April 20, 2000). "Hospital Cancer Cash Plea". The Independent. p. 3.
- ↑ Smith, Peter Lawrence; Piadel, Katarzyna; Dalgleish, Angus George (2021-11-25). "Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy". Vaccines. 9 (12): 1392. doi:10.3390/vaccines9121392. ISSN 2076-393X. PMC 8708201 Check
|pmc=value (help). PMID 34960140 Check|pmid=value (help). - ↑ Copier, John; Bodman-Smith, Mark; Dalgleish, Angus (April 2011). "Current status and future applications of cellular therapies for cancer". Immunotherapy. 3 (4): 507–516. doi:10.2217/imt.11.18. ISSN 1750-7448. PMID 21463192.
- ↑ Liu, Wai M.; Dalgleish, Angus G. (June 2012). "The potential beneficial effects of drugs on the immune response to vaccination". Seminars in Oncology. 39 (3): 340–347. doi:10.1053/j.seminoncol.2012.02.012. ISSN 1532-8708. PMID 22595056.
This article "Institute for Cancer Vaccines and Immunotherapy" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Institute for Cancer Vaccines and Immunotherapy. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
